· Koki Sato to lead Takeda’s business in India, ensuring patient access to highly innovative medicines
· Seasoned biopharmaceutical leader with over 17 years of experience across geographies
01 April, 2020: Takeda India announced today the appointment of Koki Sato as the Country Head for the Company’s India business. In his current capacity, he will lead the company’s operations with a focus on the expansion of patient access to Takeda’s highly innovative portfolio in the country.
Koki joined Takeda in 2003 and, since then, grew within the company to hold various senior international roles across multiple functions, including Commercial Operations, Finance, and HR. Prior to this role, Koki was the General Manager of Ukraine, Belarus, and Moldova (UBM) Cluster in Takeda’s ICMEA* Area.
Commenting on his new role, Koki Sato said, “India is of significant importance for Takeda and we endeavor to develop initiatives which will lead to enhanced patient access to our highly innovative medicines locally. We remain committed to serving India’s patients, and aim to bring newer therapies for rare diseases, gastroenterology, and oncology to them in the coming years, along with hopefully, our Dengue vaccine candidate.”
Across its ICMEA* Area, and more broadly across the countries that span its Growth & Emerging Markets Business Unit, Takeda collaborates with healthcare providers, governments and regulators, to ensure that its portfolio of innovative medicines is made available to patients as quickly and safely as possible.
Koki will be officially assuming his position from April 1, 2020. He is a Japanese national and holds a Bachelor of Arts degree in Political Science and Economics from Waseda University, Japan.
* ICMEA: India, the Commonwealth of Independent States, the Middle East (including Turkey), & Africa
– ENDS –
About Takeda India
Takeda India is part of Takeda Pharmaceutical Company Limited’s group of companies, headquartered in Japan. In the country, the company currently focuses on the therapeutic areas of Rare Diseases, including Hemophilia and Lysosomal Storage Disorders and plasma-derived therapies. Takeda has a presence across the Indian subcontinent, including in Sri Lanka, Nepal, and Bangladesh.
About Takeda Pharmaceuticals
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (G.I.), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Portal Instruments nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.
City Today News